Advocacy News

California Committee Advances Copay Accumulator Bill.  The California Senate Committee on Health unanimously advanced SB 1199, legislation that. would ban copay accumulator programs, on April 22. ASCO supported the bill along with the  Association of Northern California Oncologists and the Medical Oncology Association of Southern California. 

Corporate Member News

• Bristol Myers Squibb invites ANCO members to join them at ASCO for their 7th annual gathering to discuss ongoing efforts to Conquer Veteran Cancer, Together.  The event will take place on Sunday, May 31, 2026, from 9:30–11:30 AM CT at the Hyatt Regency McCormick Place (Regency Ballroom AB).

• Tarlatamab-dlle (IMDELLTRA®) is an NCCN® Category 1, Preferred subsequent treatment for adult patients (PS 0-2) with ES-SCLC who have progressed on or after platinum-based chemotherapy.  To access the full recommendations, please visit the NCCN® website: SCLC Guidelines.

Read More

• FDA approves Lumakras® (sotorasib), Amgen in combination with vectibix® (panitumumab) for chemorefractory kras G12C-mutated metastatic colorectal cancer.

Read More

• FDA grants full approval to Amgen's IMDELLTRA® in extensive stage small cell lung cancer. 

Read More

• BeOne Medicines received accelerated approval from the Food and Drug Administration for Beqalzi, a treatment aimed at certain lymphoma patients.

Read More

• The Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

Read More

• The Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.

Read More

Coding and Reimbursement Updates

• This Month’s E-Reiumbursement Newsletter from Bobbi Buell for April 23, 2026